National Lipid Association Issues Statement on the Relationship Between Increased Body Fat And Abnormal Blood Cholesterol / Lipid Levels

Oxford, May 30, 2013

Following a National Lipid Association (NLA) Consensus Conference held September 16, 2012, national leaders in the field of lipidology authored a consensus statement representing the most comprehensive review yet published on the impact of disturbances in calorie balance on lipid and cholesterol levels. Lipid specialists are health care professionals whose aim is to reduce deaths related to high cholesterol and other cardiometabolic disorders. The statement provides the best scientific support to date on the connection between obesity and heart disease. Their conclusions were published in Journal of Clinical Lipidology today.

In their statement, the authors—Harold Bays, MD, Peter P. Toth, MD, PhD, Penny Kris-Etherton, PhD, RD, Nicola Abate, MD, Louis Aronne, MD, W. Virgil Brown, MD, J. Michael Gonzalez-Campoy, MD, PhD, Steven Jones, MD, Rekha Kumar, MD, Ralph La Forge, MSc, and Varman Samuel, MD, PhD—describe how being overweight/obese and/or gaining weight and, specifically increasing body fat, may precipitate the development of “sick fat,” which is an important contributor to unhealthy levels of blood cholesterol and increased risk of cardiovascular disease. They also describe how weight loss and reduction in body fat may improve blood lipid levels and decrease risk of heart disease.

The review is detailed and expansive in scope, with an emphasis on mechanisms accounting for insulin resistance and increased risk for diabetes, so often found in overweight and obese patients. The impact of body fat on specific lipid parameters is also explored, including triglyceride, high density lipoprotein cholesterol (the so-called “good” cholesterol), and low density lipoprotein cholesterol (the “bad” cholesterol) levels, as well as how abnormal levels of these blood lipids are improved by therapies directed towards assisting patients with weight reduction.

Highlighted therapies include an extensive review of nutritional intervention, physical activity, weight management, drug therapy, and bariatric surgery. These interventions not only improve the weight of patients, but also improve their metabolic health by beneficially impacting blood lipid and cholesterol levels with an accompanying reduction in risk for heart disease.

This landmark consensus statement representing the most comprehensive review of this topic to date validates what is known by clinicians and patients alike - that increases in body fat may worsen certain types of cholesterol / blood lipid levels.

“This consensus statement is an important step in better understanding the relationship between increased body fat, and the many adverse health issues it has on patients,” said Harold Bays, MD, one of the authors. “Both clinicians and patients now have better scientific support for not only how excess calories and reduced physical activity may adversely affect body weight and heart disease risk, but also the degree by which interventions that help reduce body fat in overweight patients have the potential to improve certain types of cholesterol levels, and improve the health of patients.” 

# # #

Notes for Editors
“Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association” by Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. It appears in Journal of Clinical Lipidology, in press, published by Elsevier; and is now available online on ScienceDirect.

Full text of the article is available to credentialed journalists upon request; contact newsroom@elsevier.com or at +31 20 485 3564. Journalists wishing to interview the authors, or for more detailed information contact Judi Spann, National Lipid Association at +1 850 322 9817 or JSpann@LeadingStar.com.

About the Journal of Clinical Lipidology
The Journal of Clinical Lipidology is the official journal of the National Lipid Association and is published six times a year. The journal supports the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal's readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. www.lipidjournal.com / www.journals.elsevier.com/journal-of-clinical-lipidology

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Tamara Lucas
Elsevier
+44 1865 843658
t.lucas@elsevier.com